Globus Medical filings document formal disclosures for a medical device company focused on musculoskeletal solutions and enabling technologies. Recent Form 8-K reports furnish quarterly and annual operating results, preliminary sales information, financial guidance and related press releases covering net sales, earnings measures, cash flow and segment commentary.
The company’s proxy materials cover board elections, governance practices, executive compensation, equity awards and annual meeting matters. Other current reports document leadership transitions, director departures and related governance events, tying the filing record to Globus Medical’s operating performance, management structure and public-company reporting obligations.
GMED submitted a notice of proposed sale for 20,000 common shares via a cashless stock option exercise dated 02/25/2026. The filing lists shares outstanding 135,253,051 as of 02/25/2026. It also discloses prior sales by Kelly Huller: 10,000 shares on 02/12/2026 for $876,000 and 7,500 shares on 11/25/2025 for $674,619.
Globus Medical, Inc. files its annual report describing a fast-growing musculoskeletal and enabling-technologies business built around spine, orthopedics, biologics, neuromodulation and surgical robotics. The company reported 9 new product launches in 2025 and operates in 65 countries, with international sales representing about 19.4% of 2025 revenue.
Globus highlights two major recent deals: the 2023 stock-for-stock NuVasive merger, which broadened its spine and enabling technologies portfolio, and the 2025 Nevro acquisition, adding the HFX spinal cord stimulation platform for chronic pain in an all-cash transaction at $5.85 per Nevro share. As of February 20, 2026, Class A common shares outstanding totaled 135,253,051.
The report outlines extensive product families in Musculoskeletal Solutions and Enabling Technologies, including ExcelsiusGPS robotics and the expanding Excelsius ecosystem. It also discloses an open July 2024 FDA warning letter tied to complaint-handling and medical device reporting procedures for the ExcelsiusGPS robotic system, though the letter noted no safety concerns or manufacturing issues.
Globus Medical reported a strong finish to 2025 with robust growth in sales, profit and cash flow. Fourth quarter 2025 worldwide net sales were $826.4 million, up 25.7% year over year, while GAAP net income rose to $140.6 million and GAAP diluted EPS reached $1.03, with non-GAAP diluted EPS at $1.28.
For full year 2025, worldwide net sales were $2,938.9 million, up 16.7%, and GAAP net income grew to $537.9 million, driving GAAP diluted EPS of $3.92 and non-GAAP diluted EPS of $3.98. Base business net sales excluding Nevro were $2,645.3 million, up 5.0%, highlighting meaningful contribution from the Nevro acquisition.
Adjusted EBITDA for 2025 was $919.6 million, or 31.3% of net sales, and free cash flow reached $588.8 million. Management reaffirmed 2026 revenue guidance of $3.18–$3.22 billion and raised non-GAAP diluted EPS guidance to $4.40–$4.50, signaling confidence in continued growth and margin expansion.
Globus Medical executive Kelly Huller, EVP, General Counsel and Corporate Secretary, reported an option exercise and share sale. On February 12, 2026, she exercised stock options for 10,000 Class A shares at $45.64 per share, converting a fully vested grant from February 2018.
The same day, she sold 10,000 Class A shares at $87.67 per share in an open-market transaction, leaving her with 0 directly owned shares and 0 remaining options from this grant. The sale was executed under a pre-arranged Rule 10b5-1 trading plan dated November 12, 2025.
An insider of GMED has filed a Form 144 notice to sell 10,000 shares of common stock through Raymond James & Associates on the NYSE. The shares have an aggregate market value of about $876,000 based on the figures disclosed.
The securities were acquired on 02/12/2026 via a cashless option exercise from the issuer, with the same date listed as the payment date. Over the prior three months, the same seller, Kelly Huller, sold 7,500 common shares for gross proceeds of about $674,620.
Globus Medical director Leslie V. Norwalk received a grant of 15,000 stock options for Class A common stock. The options carry an exercise price of $94.15 per share and were granted as a derivative equity award.
According to the filing, these options were granted on January 21, 2026, will vest on January 1, 2027, and expire on January 21, 2036. After this grant, Norwalk beneficially owns 15,000 derivative securities directly, reflecting a standard director compensation award rather than an open-market transaction.
Globus Medical Inc. reported a new stock option grant to its President and CEO, Keith W. Pfeil. On January 21, 2026, Pfeil received stock options giving him the right to buy 100,000 shares of Class A common stock at an exercise price of $94.15 per share. The options were granted at no cost to him as compensation and expire on January 21, 2036.
The award vests over four years, with one-quarter of the options vesting on January 1, 2027 and the remaining options vesting in equal monthly installments (1/48 of the total) each month thereafter. All 100,000 options are reported as held directly by Pfeil following this grant.
Globus Medical Senior Vice President and CFO Kyle Kline received a grant of 30,000 stock options to buy Class A common stock at an exercise price of $94.15 per share. The options were granted on January 21, 2026 and were reported as directly owned by Kline. They vest over a four-year period, with one-quarter vesting on January 1, 2027 and the remaining three-quarters vesting in equal monthly installments of 1/48 of the grant each month thereafter, ending on the stated expiration date of January 21, 2036.
Globus Medical Inc. reported that Executive Chairman and director Paul David C, who is also a 10% owner, received a grant of stock options. On January 21, 2026, he was awarded 100,000 stock options to buy Class A common stock at an exercise price of $94.15 per share, with the options themselves granted at a cost of $0.
The options vest over four years, with one quarter vesting on January 1, 2027 and the remaining three quarters vesting in equal monthly installments over the following three years. After this grant, he beneficially owns 100,000 derivative securities directly in the form of these options.
Globus Medical Inc. director Douglas Robert Andrew received a new stock option grant. On January 21, 2026, he was awarded options to buy 15,000 shares of Class A common stock at an exercise price of $94.15 per share. The filing shows these options were granted for no cash payment at grant.
According to the disclosure, the options will vest on January 1, 2027, meaning they become exercisable on that date, and they expire on January 21, 2036 if not exercised. Following this grant, he beneficially owns 15,000 derivative securities directly in the form of these options.